FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Posted: January 27, 2025 at 2:49 am

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment

See the original post here:
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Related Posts